Anju Chatterji

Anju Chatterji has served as Senior Vice President, Biologics Development & Manufacturing at Catalyst since September 2020. Before this position, Dr. Chatterji was at Exelixis, leading biologics development and manufacturing. Dr. Chatterji previously held the role of a VP, Drug Substance Development and Manufacturing at Catalyst starting in May 2019, providing effective leadership and technical guidance for the establishment and implementation of the CMC strategy for clinical manufacturing of CBIO’s biologics portfolio. Dr. Chatterji originally joined Catalyst in May 2018 as Senior Director of CMC Development and External Manufacturing, overseeing process and analytical method development, qualification and validation, as well as manufacturing of bulk drug substance.

Prior to Catalyst, she served as Director of Technical Development for three years at Grifols, where she provided strategic leadership for Grifols’ process and technology development organization. Before Grifols, Dr. Chatterji held various leadership positions at Novartis in its manufacturing sciences and technology department, and at Bayer HealthCare in its global biological development and manufacturing sciences department for six years, where she was a process development scientist and in API operations for two years.

Dr. Chatterji began her career as a BOYSCAST research fellow at the Scripps Research Institute, La Jolla.

Dr. Chatterji holds a Ph.D. in Molecular Virology from the Indian Agricultural Research Institute.